There’s a first time for everything

Posted March 3rd, 2011 in Uncategorized

I’ve decided it’s time to experiment with blogging about the biotech venture ecosystem.  I’d like to call it a “pilot study”.  If it ends up being safe and effective over the next few months, I’ll continue.  If not, I’ll terminate the program and stick to my day job.

But why waste time on a blog?  I guess there are three reasons.

First, the life science venture community needs more voices in the blogosphere, as others have mentioned.  Despite nearly 30% of total venture dollars going into the Life Sciences, we probably represent <1% of the voices in the startup venture cyber-community.  That’s a significant under-weighting.  Almost very Tech VC franchise out there has at least one good blogger.  Take my partner Fred Destin here at Atlas.  I have taken the challenge from Fred and others to give it a shot.

Second, by nature I’m a scientist who loves data, and I like sharing data-informed perspectives on life science venture market, like a few of the recent Nature Biotech pieces I’ve written.  I think the biotech world needs more analytical robustness and transparency, and a lot less myth and mystery; I will try to add a little rigor to the field.

Third, I’ve just entered the social media world with occasional micro-blogging on Twitter, and I’m fascinated by its ability to connect.  And “proper” blogging feels like the natural extension of it.  When Mike Gilman, CEO of an Atlas-backed company called Stromedix, was named a Top 10 Twitter user to follow in Boston by Scott Kirsner in mid-December last year, I had him come by the office and teach me to Tweet.   In his own words, he’s now a Jedi Master at that stuff and has brought me up to speed on Hootsuite and things like URL shorteners.

So there you have it, a few of my reasons for experimenting with a blog.

What will I blog about?  I guess I’d break it down into a few buckets: (a) analysis on the biotech sector, and the venture capital model, returns from specific deals etc…; (b) the evolution of the ecosystem with new business models, companies, and concepts; (c) cool life science findings or papers and how at least one VC looks at it.

If anyone ever reads it, I’d welcome feedback on this blog – whether I should just quit blogging and focus on my day job, comments on my blog posts, or if you have a particular topic you think I should write about.

My blogging expectations aren’t high – if I can do two posts a week, I’ll feel lucky.  And certainly not busy enough.

Now off to think up something to write.

This entry was posted in Uncategorized. Bookmark the permalink.
  • Great to hear additional input from someone interested and investing in the life science sector. I’m looking forward to hearing more.

  • Ellen Clark

    I saw your tweet about your blog and I will be following you. I recruit for the biotech space and I am always looking for good material to keep me well informed about what is going on in the industry. I wish you much success and look forward to future posts.

  • Anonymous

    Welcome Bruce! Can’t wait to hear more from the LS side of the world.

  • Lev Osherovich

    Looking forward to reading your insights.

  • Anonymous


    Glad you are doing this. Agree that there is way too little life science posting out there. Look forward to reading more.

  • Finally we will get to know what our Life Sciences colleagues actually do all day. What a great initiative. Within 6 months our internal network will be updated with a link to this blog under the “Knowledge Management” tab and if more than 80% of concerned employees click on the link at least once, we will recommend to Corporate Communications that one more employee be allowed to blog and see if the success rate is consistent on a larger sample. Finally, we have a social media strategy. I feel like f%%%% hubspot 🙂

  • Anonymous

    Best of luck with this!

  • Cjfisherjr


    Great initiative! I look forward to reading your insights on your blog

  • Melanie

    Hi Bruce, A good initiative. I will be joining you on my blog Have you heard of the Arch2POCM consortium ideas from Aled Edwards, Chas Bountra and Stephen Friend? Please look at This is an exciting gathering of thought leaders to address the inefficiencies of early drug target validation through a consortium and IP free Public/private partnership. Fantastic guys and a good idea. Melanie Lee

  • Page

    Bruce, I will follow with great interest. It has been very interesting to see the biotech world from multiple angles. We in large pharma still desperately need to gain innovation from biotech, so we need to find a way to successfully foster the first stage of innovative product discovery.

  • Jackson

    As a co-founder of a fledgling Biotech start-up, I want to express my sincere gratitude for your efforts. I’ve been searching all over the web for some good biotech start-up blogs but all I came across are Tech ones. While some topics Tech VC cover are quite relevant and I still read pieces from asktheVC and Paul Graham for general information and inspiration, they cannot substitute domain-specific insights. Your blog is the best one I discovered so far and I have been systematically reading all your posts ever since. I’m sure there are many other people like me who can benefit a lot from your blog, so please don’t give up!